Theravance Biopharma Inc
Research Theravance Biopharma Inc (TBPH) on Bullrun: market cap USD 883.70M, P/E 16.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTBPH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 883.70M
- P/E16.9
- Financial periodQ1 2026
- RevenueUSD 17.70M
- Net incomeUSD 114.54M
- Free cash flowUSD 268.74M
Valuation Snapshot
latest market cap is USD 883.70M; P/E is 16.9.
Peer valuation comparison
Latest P/E is 16.87x versus a Healthcare sector median of 24.46x (31.0% below).
Latest P/E is 16.87x versus a United States median of 24.87x (32.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 107.46M | USD 105.90M | USD 238.50M | n/a | 2.06 | USD 167.81M | USD 42.70M | USD 296.72M |
| FY2024 | USD 64.38M | -USD 56.42M | -USD 11.87M | n/a | -1.15 | USD 37.80M | USD 49.82M | USD 175.55M |
| FY2023 | USD 57.42M | -USD 55.19M | -USD 29.49M | n/a | -1 | USD 39.55M | USD 0 | USD 213.00M |
| FY2022 | USD 51.35M | USD 872.13M | -USD 187.56M | n/a | 11.85 | USD 298.17M | USD 675.34M | USD 441.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 883.70M | 16.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 955.49M | 9.2 | n/a | n/a |
| 2024 | 2024-12-31 | USD 465.52M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 559.73M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 755.85M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 822.51M | n/a | n/a | n/a |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Theravance Biopharma Inc's market cap?
Theravance Biopharma Inc's market capitalization is USD 883.70M.
What is Theravance Biopharma Inc's P/E ratio?
Theravance Biopharma Inc's price-to-earnings (P/E) ratio is 16.9.
What does Theravance Biopharma Inc do?
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc.